Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company profile
Ticker
PFE
Exchange
Website
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Canada Holdings, L.P. • Arena Pharmaceuticals Development GmbH ...
PFE stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Tim Buckley Elected to Pfizer’s Board of Directors
15 Oct 24
SC TO-I/A
Issuer tender offer statement (amended)
13 Sep 24
SC TO-I/A
Issuer tender offer statement (amended)
22 Aug 24
SC TO-I
Issuer tender offer statement
12 Aug 24
10-Q
2024 Q2
Quarterly report
5 Aug 24
SC TO-C
Information about tender offer
31 Jul 24
SC TO-C
Information about tender offer
30 Jul 24
8-K
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
30 Jul 24
SC TO-C
Information about tender offer
26 Jul 24
8-K
Departure of Directors or Certain Officers
26 Jul 24
Transcripts
PFE
Earnings call transcript
2024 Q2
30 Jul 24
PFE
Earnings call transcript
2024 Q1
1 May 24
PFE
Earnings call transcript
2023 Q4
30 Jan 24
PFE
Earnings call transcript
2023 Q3
31 Oct 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q1
2 May 23
PFE
Earnings call transcript
2022 Q4
31 Jan 23
PFE
Earnings call transcript
2022 Q3
1 Nov 22
PFE
Earnings call transcript
2022 Q2
28 Jul 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Oct 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn |
Cash burn (monthly) | (no burn) | 131.25 mm | 34.33 mm | 346.92 mm | 593.67 mm | (no burn) |
Cash used (since last report) | n/a | 492.85 mm | 128.92 mm | 1.30 bn | 2.23 bn | n/a |
Cash remaining | n/a | 630.15 mm | 994.08 mm | -179.69 mm | -1.11 bn | n/a |
Runway (months of cash) | n/a | 4.8 | 29.0 | -0.5 | -1.9 | n/a |
Institutional ownership, Q2 2024
65.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2828 |
Opened positions | 261 |
Closed positions | 213 |
Increased positions | 1129 |
Reduced positions | 1196 |
13F shares | Current |
---|---|
Total value | 100.78 tn |
Total shares | 3.74 bn |
Total puts | 107.54 mm |
Total calls | 73.07 mm |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 511.40 mm | $14.31 tn |
BLK BlackRock | 424.38 mm | $11.87 tn |
STT State Street | 287.06 mm | $8.03 tn |
Wellington Management | 166.32 mm | $4.65 tn |
Charles Schwab Investment Management | 117.28 mm | $3.28 tn |
Geode Capital Management | 115.81 mm | $3.23 tn |
Capital World Investors | 88.14 mm | $2.47 tn |
Norges Bank | 83.96 mm | $2.35 tn |
MS Morgan Stanley | 77.47 mm | $2.17 tn |
Massachusetts Financial Services | 71.79 mm | $2.01 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Oct 24 | Rady A Johnson | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 29.44 | 6 | 176.64 | 9,189 |
15 Oct 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 29.44 | 18 | 529.92 | 679,044 |
10 Oct 24 | Rady A Johnson | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 29.34 | 29 | 850.86 | 9,183 |
10 Oct 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 29.34 | 69 | 2.02 k | 679,059 |
News
Starboard Value Says Pfizer Appears To Have Overpaid For Its Post 2022 Acquisitions Based On Its Own Sales Targets
22 Oct 24
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
17 Oct 24
Bernstein Initiates Coverage On Pfizer with Market Perform Rating, Announces Price Target of $32
17 Oct 24
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
16 Oct 24
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
15 Oct 24
Press releases
Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit
22 Oct 24
ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024
16 Oct 24
Tim Buckley Elected to Pfizer's Board of Directors
15 Oct 24
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
11 Oct 24
Starboard Value Issues Letter to Pfizer's Board of Directors
10 Oct 24